Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for Gastric Intestinal Metaplasia
NCT07129460Phase 4Not yet recruiting
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, double-blind trial in gastric intestinal metaplasia (IM) comparing Berberine Group with Placebo Group (2 arms). Primary endpoints: Regression rate of gastric intestinal metaplasia based on OLGIM stage at 6 months and Progression rate of gastric intestinal metaplasia based on OLGIM stage at 6 months. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
berberine
03
Conditions
gastric intestinal metaplasia (IM)
Beyond the preview
Go deeper on NCT07129460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129460.